Measurement and impact of co-morbidity in elderly patients with advanced non-small cell lung cancer treated with chemotherapy. A phase II study of weekly paclitaxel

References

• Gridelli C, Perrone F, Monfardini S. Lung cancer in the elderly. Eur J Cancer 1997; 33: 2313–4
   PubMed Web of Science ®Google Scholar
• Souquet PJ, Chauvin F, Boisel JP, Cellerino R, Cormier Y, Ganz PA, et al. Polychemotherapy in advanced non-small cell lung cancer: A meta-analysis. Lancet 1993; 342: 19–21
   PubMed Web of Science ®Google Scholar
• Marino P, Pampallona S, Preatoni A, Cantoni A, Invernizzi F. Chemotherapy versus supportive care in advanced non-small cell lung cancer: Results of a meta-analysis of the literature. Chest 1994; 106: 861–5
   PubMed Web of Science ®Google Scholar
• Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: A meta-analysis using update data on individual patients from 52 randomized clinical trials. Br Med J 1995;311:899–909.
   PubMed Web of Science ®Google Scholar
• Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S, Jr, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003. J Clin Oncol 2004; 22: 330
   PubMed Web of Science ®Google Scholar
• Socinski MA. Single-agent paclitaxel in the treatment of advanced non-small cell lung cancer. The Oncologist 1999; 4: 408–16
   PubMedGoogle Scholar
• Lopes NM, Adams EF, Pitts TW, Bhuyan BK. Cell kill kinetics and cell cycles effects of Taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 1993; 32: 235–42
   PubMed Web of Science ®Google Scholar
• Juan O, Albert A, Ordoño F, Casany R, Carañana V, Campos JM, et al. Low-dose weekly paclitaxel as second-line treatment for advanced non-small cell luna cancer: A phase II study. Jpn J Clin Oncol 2002; 32: 449–54
   PubMedGoogle Scholar
• Charlson ME, Pompei P, Ales K, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal stusies: Development and validation. J Chron Dis 1987; 40: 373–83
   PubMedGoogle Scholar
• Kaplan MH, Feinstein AR. The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus. J Chron Dis 1974; 27: 387–404
   PubMedGoogle Scholar
• Linn Bs, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc 1968; 6: 622–6
   Google Scholar
• Cancer Therapy evaluation program. Common toxicity Criteria, Version 2.0., DCTD, NCI, NIH, DHHS; 1998.
   Google Scholar
• WHO. WHO Handbook for Reporting Results of Cancer Treatment. Geneva: WHO; 1979.
   Google Scholar
• Simon R. Optimal two-stages design for phase II clinical trials. Control Clin Trials 1989; 10: 1–10
   PubMedGoogle Scholar
• Extermann M, Overcash J, Lyman GH, Parr J, Balducci L. Comorbidity and functional status are independent in older cancer patient. J Clin Oncol 1998; 16: 247–62
   Google Scholar
• Lilenbaum RC, Herndon JE, List MA, Desch C, Watson DM, Miller AA, et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: The Cancer and Leukemia Group B (study 9730). J Clin Oncol 2005; 23: 190–6
   PubMed Web of Science ®Google Scholar
• Gridelli C, Perrone F, Gallo C, Cigorali S, Rossi A, Piantedosi F, et al. Chemotherapy for elderly patients with advanced non-small-sell lung cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Nat Cancer Inst 2003; 95: 362–72
   PubMed Web of Science ®Google Scholar
• Gridelli C, Shepherd FA. Chemotherapy for elderly patients with non-small cell lung cancer. A review of the evidence. Chest 2005; 128: 947–57
   PubMed Web of Science ®Google Scholar
• Fidias P, Supko JG, Martins R, Boral A, Carey R, Grossbard M, et al. A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. Clin Cancer Res 2001; 7: 3942–9
   PubMed Web of Science ®Google Scholar
• Garbo L, Marsland T, Garfield D, Khan M, Asmar L. A phase II study of weekly paclitaxel (Taxol® in stage IIIB, IV or relapsed after local therapy, non-small cell lung cancer (NSCLC) patients with performance status 2 and/or ≥70 years (yrs) of age, with (Paraplatin® administered at disease progression [abstract]. Proc Am Soc Clin Oncol 2001; 20: 267b
   Google Scholar
• West W, Birch R, Sysel IA, Schell FM, Liebmann J, Tongol J, et al. A phase II trial of weekly paclitaxel in elderly patients or those with decreased performance status with advanced non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 2001; 20: 258b
   Google Scholar
• Extermann M. Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol 2000; 35: 181–200
   PubMed Web of Science ®Google Scholar